Biotech Entrepreneur Aldag Inspired By Italy's Genespire
New Chairman of Milan-Based Gene Therapy Firm
Jörn Aldag, who has over 20 years of leadership experience in the life sciences industry, including CEO of gene therapy pioneer uniQure, tells Scrip that the research carried at the world-class Italian research institute SR-Tiget.
You may also be interested in...
Tecentriq is the only checkpoint inhibitor to get approval for first-line TNBC but failure in a second study for that indication will encourage rival Merck & Co with Keytruda nearing approval.
Despite COVID-19, Horizon Therapeutics has pulled off a spectacularly successful launch of its thyroid eye disease therapy, Tepezza, thanks to pre-commercial activities that led to a high level of initial patient and prescriber awareness, and market access teams securing a decent reimbursement rate.
The French company's hopes of joining Aimmune's Palforzia on the peanut allergy market soon have been shattered after US regulators issued a complete response letter to its Viaskin Peanut patch. A lot now depends on how much work DBV will have to do to satisfy the FDA.